Together, these in vitro results demonstrate that ARV@PDSA treatment not only facilitated the BRD4 degradation but also efficiently drugged the undruggable oncogene c‐Myc, again highlighting the promise of the Nano‐PROTACs strategy for anti‐tumor therapy. The gene discussed is BRD4; the disease is neoplasm.